REMSleep Receives Medicare PDAC Coding Approval for Complete DeltaWave Product Portfolio
MWN-AI** Summary
**REMSleep Secures Medicare Coding Approval for DeltaWave Product Line**
REMSleep Holdings, Inc. (OTCQB: RMSL), a prominent developer of the FDA-cleared DeltaWave™ nasal pillow system, announced on January 30, 2026, that it received Healthcare Common Procedure Coding System (HCPCS) approvals from the Pricing, Data Analysis, and Coding (PDAC) contractor. This important milestone enables durable medical equipment (DME) providers to bill Medicare and private insurers for all configurations of the DeltaWave system, facilitating full commercial launch capabilities.
The coding approvals finalize the regulatory requirements essential for REMSleep’s extensive distribution effort. Following an expanded FDA 510(k) clearance granted on January 7, the company is set to deploy its DeltaWave products nationwide across home care and institutional settings. “This is a critical milestone for our DME partners,” noted Thomas Wood, CEO of REMSleep, underscoring the importance of the combined regulatory approvals and robust inventory in launching the product.
The DeltaWave portfolio was developed with insights from early adoption partners who provided feedback during a Q4 2025 soft launch. Adjustments included various component combinations and sizing tailored to meet patient needs, particularly for sleep laboratories and DME providers preferring either complete systems or individual components.
Since December 2025, REMSleep has achieved key developments, including FDA clearance expansions and market validations. With the pathway cleared for national distribution, the company is initiating a three-channel strategy focusing on DME providers, sleep laboratory partnerships, and institutional sales.
With all approvals secured, REMSleep is poised to meet diverse market demands, moving forward into a full-scale launch for its innovative sleep therapy solution.
MWN-AI** Analysis
REMSleep Holdings, Inc. (OTCQB: RMSL) has recently achieved a significant milestone by securing PDAC coding approval for its DeltaWave product portfolio, paving the way for full-scale commercial launch. This achievement allows durable medical equipment (DME) providers to bill Medicare and private insurers, greatly enhancing the market accessibility of DeltaWave, a nasal pillow system designed for sleep therapy.
While REMSleep is set to penetrate the sleep therapy market during an essential time, prospective investors should consider several market dynamics. Health care providers increasingly seek innovative, cost-effective solutions for treating sleep apnea and related conditions, a trend supported by the growing awareness of sleep health's impact on overall wellness. By aligning its product offerings with provider needs—such as various configurations for DME providers and sleep laboratories—REMSleep is strategically positioned to capitalize on this demand.
Moreover, the company's three-channel commercial strategy—targeting DME/HME providers, sleep laboratories, and institutional sales—reflects a sustainable approach to market penetration. It is prudent to assess the execution of this strategy, particularly the cultivation of partnerships with DME providers and institutions that treat the substantial population suffering from sleep disorders.
Investors should also keep an eye on reimbursement trends, as successful integration into payor networks is critical for ensuring broader adoption. Although approval for HCPCS codes opens financial avenues for both REMSleep and its partners, the ultimate uptake depends on the satisfaction of the provider community and patient outcomes.
In conclusion, REMSleep's recent milestones position it favorably within a rapidly growing sector. However, investors should remain vigilant regarding market reception, competitive positioning, and reimbursement practices as they evaluate the potential of RMSL in their portfolios.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BLACKSHEAR, GA - January 30, 2026 (NEWMEDIAWIRE) - REMSleep Holdings, Inc. (OTCQB: RMSL), a developer of the FDA-cleared DeltaWave™ nasal pillow system, today announced that it has received Healthcare Common Procedure Coding System (HCPCS) approvals from the Pricing, Data Analysis, and Coding (PDAC) contractor for the entire DeltaWave product portfolio. This approval allows durable medical equipment (DME) providers to bill Medicare and private insurance payors for all configurations of the DeltaWave system.
The PDAC coding approvals represent the final regulatory requirement needed for REMSleep’s full commercial launch. With expanded FDA 510(k) clearance granted on January 7 and full reimbursement coding now in place, REMSleep is poised to begin nationwide distribution across home care, institutional, and sleep laboratory settings.
“This marks a critical milestone for our DME partners who now have everything they need the expanded FDA clearance, HCPCS codes for all configurations, and a fully stocked inventory,” said Thomas Wood, CEO and founder of REMSleep. “We are excited to proceed with the full commercial launch of DeltaWave, offering a solution that meets the diverse needs of the sleep therapy market.”
Expanded Product Portfolio Reflects Customer Feedback
The DeltaWave product portfolio expansion was informed by feedback from early adoption partners during REMSleep’s Q4 2025 soft launch. DME providers and sleep laboratories identified specific component combinations and sizing variations that were required to better serve their patient populations.
“Some providers prefer complete systems, while others need separate components tailored to their patient demographics,” explained Jeff Marshall, REMSleep’s operations manager. “Sleep labs also requested pillow-only options for diagnostic titration. This feedback was integral in shaping the final product offering.”
Timeline of Regulatory and Commercial Milestones
Since December 2025, REMSleep has achieved a series of key operational milestones:
- January 7, 2026: FDA 510(k) clearance expanded to include a wider patient demographic and multiple care environments.
- December 9, 2025: Supplemental 510(k) application submitted to the FDA.
- December 16, 2025: Infrastructure buildout, including ERP systems and sales force training, announced.
- December 23, 2025: Early market validation received, with zero product returns and repeat orders.
- January 21, 2026: Complete PDAC coding approval for all DeltaWave configurations.
“We have transitioned from a soft launch with a limited FDA clearance to being fully prepared for national distribution,” Wood said. “This is a significant leap toward providing a complete solution for our customers.”
Commercial Strategy and Market Entry
With regulatory and reimbursement barriers now cleared, REMSleep is activating its three-channel strategy:
- DME/HME Rescue Mask Positioning: Sales representatives are reaching out to DME providers, targeting the 20-30% of CPAP patients who fail their initial mask. All billing codes are in place to support this market.
- Sleep Laboratory Partnerships: DeltaWave will be available for use in diagnostic titration, ensuring that patients can access the same mask through insurance after their lab visit.
- Institutional Sales: REMSleep will begin supplying DeltaWave to hospital respiratory departments and long-term care facilities for use in BiPAP and ventilation support.
“We are now fully equipped to execute our strategy across multiple channels,” said Marshall. “With all regulatory approvals in place, we are ready to move forward with our full-scale launch.”
About REMSleep Holdings, Inc.
REMSleep Holdings, Inc. (OTCQB: RMSL) is a medical device company focused on enhancing outcomes for patients requiring positive airway pressure therapy. The company’s DeltaWave™ nasal pillow system is FDA-cleared for use with CPAP, BiPAP, and other non-invasive positive pressure devices in both home and institutional settings. All DeltaWave products have received PDAC coding approval for Medicare and private insurance reimbursement.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to: market acceptance of the DeltaWave system, DME provider adoption rates, the company’s ability to achieve targeted sales volumes, reimbursement practices by private payors, and general market conditions. REMSleep undertakes no obligation to update these forward-looking statements.
Contact:
Thomas Wood, CEO
REMSleep Holdings, Inc.
912-590-2001
twood@remsleep.com
View the original release on www.newmediawire.com
FAQ**
How does REMSleep Holdings Inc RMSL plan to differentiate the DeltaWave system in the competitive sleep therapy market following its full commercial launch?
What strategies are in place to ensure DME provider adoption and maximize the market acceptance of REMSleep Holdings Inc RMSL's DeltaWave product portfolio?
How does REMSleep Holdings Inc RMSL intend to address potential reimbursement challenges from private payors and improve billing practices for its DeltaWave system?
What key metrics will REMSleep Holdings Inc RMSL use to evaluate the success of its nationwide distribution strategy for the DeltaWave nasal pillow system in 2026 and beyond?
**MWN-AI FAQ is based on asking OpenAI questions about REMSleep Holdings Inc (OTC: RMSL).
NASDAQ: RMSL
RMSL Trading
-4.35% G/L:
$0.0066 Last:
233,005 Volume:
$0.00669 Open:
